In the
case of most progressive illnesses, early detection is key, and this is
particularly true for both primary types of lung cancer, NSCLC and SCLC
(non-small cell lung cancer and small cell lung cancer), as well as the “Super
Bug” known as MRSA (Methicillin-resistant Staphylococcus aureus). MRSA, a kind
of robust and highly persistent staph bacterium, is a major, growing concern
for hospitals, due in large part to this nasty little bug’s ability to shrug
off the most powerful antibiotics available today. Whether a given infection is
technically classified as a CA-MRSA (community-acquired) or HA-MRSA
(hospital-acquired), the patient end point is invariably a healthcare facility,
where the bug may spread and/or lie dormant, posing a serious propagation
threat, both for patients and healthcare professionals alike.
Surgical
site infection (SSI) continues to be one of the most dangerous postoperative
complications, accounting for roughly one third of all HAI’s (hospital-acquired
infections) and of that approximately 33% of all HAI’s, nearly 30% are
MRSA-positive. MRSA loves to live in the skin and is often hiding in places
like the nose, throat and armpits of carriers, making successful decolonization
of a given subject extremely tricky. Decolonization requires prolonged
treatments, like 5 to 10 days of twice-daily mupirocin in the nose, oral
rinsing with 0.2% chlorhexidine three times a day for a week to try and clear
the throat, or dilute bleach baths for as long as three months in order to
decontaminate carriage sites on the body.
The global
HAI testing market ran about $2.2B just two years prior and was recent forecast
by Transparency Market Research as topping out around $7.5B in 2019, on a CAGR
of roughly 19.3%, making this a huge target for developers and an area of
considerable interest for investors as well. The ability to test early and
actually prevent more serious/costly issues is an extremely attractive approach
for curbing the soaring overall healthcare cost impacts to various economies,
making the emergence of detection devices a highly sought-after possibility.
NSCLC lung
cancer accounts for as much as 90% of all cases and the global market for just
drugs to treat such cancer is on-track to hit around $6.9B by 2019 on a 4.84%
CAGR, with the broader therapy market being much larger and on-track to hit
around $7.9B by 2020 (GBI Research). With a projected CAGR somewhere in the
neighborhood of 6.6%, as new drugs and premium therapies, like second-line and
squamous cell treatment continue to emerge and offset generic chemotherapies,
the NSCLC treatment market is growing just as fast as a malignant cancer
itself. The biggest players like AstraZeneca (NYSE:AZN), Roche (OTCQX: RHHBY)
and Merck (NYSE: MRK) will continue to drive the trend towards market
segmentation in lung cancer treatment with premium therapies and new drugs,
according to GBI Research.
The recent
announcement by Zenosense, Inc. (OTCQB: ZENO), which is currently developing
two types of electronic nose devices via contract with Zenon Biosystem that
continuously monitor for and accurately discriminate hallmark VOCs (volatile
organic compounds) of key MRSA and lung cancer biomarkers, that their common
stock has been approved by the DTC (Depository Trust Corporation) for DWAC/FAST
transfer, makes this small sector up-and-comer even more attractive as a
vehicle for investors to tap into these markets. As a developer of detection
devices that could save lives while grabbing market share from the treatment
end of the game, ZENO’s technology is disruptive and could change the entire
MRSA/SA and lung cancer markets on a fundamental level. DWAC/FAST transfer
approval of the company’s common stock, using ZENO’s transfer agent, Action
Stock Transfer Corporation, confers considerable benefits to shareholders as
well. Including rapid brokerage account deposits and withdrawals, elimination
of risk associated with handling physical certificates, and the higher
liquidity that comes along with such enhanced share accessibility/availability.
Zenosense
announced manufacturing of their pre-commercial prototype lung cancer detector
early last month (November 4), highlighting key features like the device’s
ability to rapidly discriminate against background VOCs in the breath of
patients and hone in on the target lung cancer VOC biomarkers. Development
partner Zenon Biosystem has come up with some cunning adaptations of the
detection pipeline, using molecular sieves in complementary layered and mixed
sensor structures, and has developed new metal oxide materials and combinations
of metal oxides not found anywhere in the commercially available sensor market
today.
Similar
breakthroughs in the development of the company’s MRSA detector, including
novel biomarker micro-separator sensor technology, has led to testing of a
prototype to measure and contrast cultures of MRSA and SA, with a subsequent
announcement in late October that the device successfully achieved a
sensibility detection rate on cultured headspace in a clinical setting of over
95% during a two-week testing period. The considerable progress ZENO has made
in a relatively short time towards commercialization of such highly accurate
early detection devices for lung cancer and MRSA/SA could potentially
revolutionize the approach to both maladies and saves countless lives.
Given the
224k or so new cases of lung cancer in the U.S. alone each year (around 160k
deaths, American Cancer Society) and CDC’s best estimates that 33% of Americans
are staph carriers, with 10.8k deaths in the each year from staph, 5.5k of
which are MRSA related, there is a massive target market for ZENO’s detection
systems.
For more
information on Zenosense, please visit: www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
No comments:
Post a Comment